Therefore, in this review article, we highlight the deleterious effect of inflammation in T2DM pathophysiology and complications, while we also elaborate on the evidence concerning the anti-inflammatory potential of novel antidiabetic medication, namely, dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.